ctDNA as a Response Biomarker in Solid-Tumor Oncology: Toward Routine Use in Drug-Development
Time: 3:05 pm
day: Day One
Details:
- Review the role of ctDNA as a biomarker of therapeutic response – challenges and opportunities
- Highlight key decision points where ctDNA is uniquely positioned to add value in drug development
- Evaluate scenarios to showcase how the routine use of ctDNA enables stronger and faster decisions by predicting response to therapy in solid tumors
